Search research articles
Contact Us
Filters
Showing results (1-10 of 29) with videos related to
Page
of 3
Sort By:
The Prostate
|
September 21, 2007
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer
Brian M Olson, Douglas G McNeel
Cancer Immunology, Immunotherapy : CII
|
February 26, 2011
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells
Brian M Olson, Douglas G McNeel
Frontiers in Oncology
|
May 9, 2013
Monitoring regulatory immune responses in tumor immunotherapy clinical trials
Brian M Olson, Douglas G McNeel
Methods in Molecular Biology (Clifton, N.J.)
|
July 2, 2009
Methods for constructing and evaluating antitumor DNA vaccines
Brian M Olson, Douglas G McNeel
Open Access Journal of Urology
|
November 8, 2013
Sipuleucel-T: immunotherapy for advanced prostate cancer
Brian M Olson, Douglas G McNeel
Expert Review of Vaccines
|
December 20, 2012
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence
Brian M Olson, Douglas G McNeel
Frontiers in Immunology
|
October 24, 2013
Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance
Brian M Olson, Jeremy A Sullivan, William J Burlingham
Expert Review of Vaccines
|
December 21, 2012
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation
Jordan E Bloom, Douglas G McNeel, Brian M Olson
Oncoimmunology
|
July 30, 2016
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
Brian T Rekoske, Brian M Olson, Douglas G McNeel
Journal for Immunotherapy of Cancer
|
July 19, 2017
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
Laura E Johnson, Brian M Olson, Douglas G McNeel
Page
of 3
Search research articles
Search
Showing results (1-10 of 29) with videos related to
Sort By:
Page
of 3
The Prostate
|
September 21, 2007
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer
Brian M Olson, Douglas G McNeel
Cancer Immunology, Immunotherapy : CII
|
February 26, 2011
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells
Brian M Olson, Douglas G McNeel
Frontiers in Oncology
|
May 9, 2013
Monitoring regulatory immune responses in tumor immunotherapy clinical trials
Brian M Olson, Douglas G McNeel
Methods in Molecular Biology (Clifton, N.J.)
|
July 2, 2009
Methods for constructing and evaluating antitumor DNA vaccines
Brian M Olson, Douglas G McNeel
Open Access Journal of Urology
|
November 8, 2013
Sipuleucel-T: immunotherapy for advanced prostate cancer
Brian M Olson, Douglas G McNeel
Expert Review of Vaccines
|
December 20, 2012
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence
Brian M Olson, Douglas G McNeel
Frontiers in Immunology
|
October 24, 2013
Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance
Brian M Olson, Jeremy A Sullivan, William J Burlingham
Expert Review of Vaccines
|
December 21, 2012
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation
Jordan E Bloom, Douglas G McNeel, Brian M Olson
Oncoimmunology
|
July 30, 2016
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
Brian T Rekoske, Brian M Olson, Douglas G McNeel
Journal for Immunotherapy of Cancer
|
July 19, 2017
Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination
Laura E Johnson, Brian M Olson, Douglas G McNeel
Page
of 3